UroGen Pharma CFO sells 2,202 shares to cover taxes

The RSUs were part of a grant representing 13,450 ordinary shares on October 8, 2024, with vesting in 3 equal annual installments from October 8, 2025.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) Chief Financial Officer Chris Degnan settled 4,483 restricted stock units into 4,483 ordinary shares on October 8, 2026. He sold 2,202 ordinary shares at $36.69 per share to satisfy withholding tax obligations upon the RSU settlement. The derivative transaction reports 4,484 restricted stock units following settlement. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Degnan Chris

Role Chief Financial Officer

Sold 2,202 shs ($81K)

Approx. gross sale proceeds $81K

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F3	4,483	$0.00	$0.00
Exercise	Ordinary Shares F1	4,483	--	--
Sale	Ordinary Shares F2	2,202	$36.69	$81K

Holdings After Transaction: Restricted Stock Units — 4,484 contracts (Direct); Ordinary Shares — 4,561 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
2. F2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
3. F3. The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.

Key Figures

Restricted stock units settled: 4,483 restricted stock units Ordinary shares acquired: 4,483 ordinary shares Ordinary shares sold: 2,202 ordinary shares +4 more

7 metrics

Restricted stock units settled 4,483 restricted stock units October 8, 2026

Ordinary shares acquired 4,483 ordinary shares Upon settlement of the RSUs on October 8, 2026

Ordinary shares sold 2,202 ordinary shares October 8, 2026

Sale price $36.69 per share Sale on October 8, 2026

Restricted stock units following transaction 4,484 restricted stock units Following the derivative transaction on October 8, 2026

Ordinary shares represented by RSU grant 13,450 ordinary shares RSUs granted October 8, 2024

Vesting installments 3 equal annual installments Beginning October 8, 2025

Key Terms

restricted stock unit, contingent right, vest, withholding tax obligations

4 terms

restricted stock unit financial

"Each restricted stock unit ("RSU")"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive one ordinary share"

vest financial

"will vest in three equal annual installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

withholding tax obligations financial

"shares sold to satisfy withholding tax obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many UroGen Pharma (URGN) shares did CFO Chris Degnan sell, and at what price?

Chris Degnan sold 2,202 ordinary shares on October 8, 2026, at $36.69 per share. The shares were sold to satisfy withholding tax obligations upon settlement of restricted stock units, and no Rule 10b5-1 plan is reported.

How many UroGen Pharma (URGN) RSUs did Chris Degnan settle?

Chris Degnan settled 4,483 restricted stock units into 4,483 ordinary shares on October 8, 2026. The derivative transaction reports 4,484 restricted stock units following settlement.

When were Chris Degnan's UroGen Pharma RSUs granted, and how do they vest?

The RSUs representing 13,450 ordinary shares were granted on October 8, 2024, and vest in 3 equal annual installments from October 8, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 12:57 PM EDT Accepted by SEC EDGAR 10/09/2026 - 12:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Degnan Chris

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	10/08/2026		M		4,483	A	(1)	6,763	D
Ordinary Shares	10/08/2026		S		2,202(2)	D	$36.69	4,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/08/2026		M			4,483	(3)	(3)	Ordinary Shares	4,483	$0	4,484	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

3. The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.

	/s/ Jason D. Smith, Attorney-in-Fact	10/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)